- WuXi XDC has partnered with Schreiner MediPharm to implement a customised light protection solution for its ADC drug clinical trials.
- The collaboration resulted in the development of a Light-Protect-Label, which safeguards light-sensitive ingredients while ensuring clinical trial integrity.
WuXi XDC, a contract research, development, and manufacturing organization (CRDMO) based in China, has announced a strategic collaboration with Schreiner MediPharm. This partnership aims to enhance the safety and efficacy of an antibody-drug conjugate (ADC) currently in clinical trials. The agreement focuses on developing an innovative light protection solution tailored for WuXi XDC’s specific needs.
The ADC drug’s light-sensitive active ingredient is lyophilised and stored in transparent vials. It is crucial to protect this ingredient from light exposure to maintain its effectiveness during the trial. Schreiner MediPharm’s Light-Protect-Label has been designed to address these requirements, offering integrated UV and light protection while blinding the investigational drug.
According to WuXi XDC, the opaque label effectively wraps around the vial, ensuring optimal light protection. The label also features a resealable inspection window, allowing for visual checks of the lyophilisate’s condition and colour before administration. This capability is vital for ensuring the medication’s efficacy.
Read about ADC Antibody Drug Conjugates CDMO Market 2024 Here.
Overview of outsourcing trends 
